These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 26790028)

  • 1. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
    Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
    Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
    Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
    Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
    Xiang QF; Zhan MX; Li Y; Liang H; Hu C; Huang YM; Xiao J; He X; Xin YJ; Chen MS; Lu LG
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):83-89. PubMed ID: 30663411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
    Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
    Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
    Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
    Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
    Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
    Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
    Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
    PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
    Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ
    Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
    Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
    Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.